Natural killer cells in the treatment of high-risk acute leukaemia

Seminars in Immunology

Volumn 26, Issue 2, 2014, Pages 173-179

  Locatelli, Franco ^a,b   Moretta, Francesca ^a   Brescia, Letizia ^a   Merli, Pietro ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Adoptive immunotherapy with NK cells; Allogeneic hematopoietic stem cell transplantation; Inhibitory and activating NK cell receptors; Innate immunity; KIR KIR ligand mismatched; Redirection of NK cell cytotoxicity

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GRANZYME; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 21; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; METHYLPREDNISOLONE; NECTIN 2; PERFORIN;

ACUTE LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; CANCER RECURRENCE; CANCER SURVIVAL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL KILLING; CYTOMEGALOVIRUS INFECTION; DONOR SELECTION; GENETIC MANIPULATION; GENOTYPE; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HIGH RISK PATIENT; HOMOZYGOSITY; HOST RESISTANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA CELL; NATURAL KILLER CELL; REVIEW; T CELL DEPLETION; T LYMPHOCYTE; ACUTE DISEASE; ALLOTRANSPLANTATION; DONOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKEMIA; METABOLISM; TRANSPLANTATION;

ACUTE DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LEUKEMIA; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84897959939     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.02.004     Document Type: Review

References (98)

1. Fridman W.H., Mlecnik B., Bindea G., Pages F., Galon J. Immunosurveillance in human non-viral cancers. Curr Opin Immunol 2011, 23:272-278.
2. Bleakley M., Riddell S.R. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol 2011, 89:396-407.
3. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999, 5:677-685.
4. Burke S., Lakshmikanth T., Colucci F., Carbone E. New views on natural killer cell-based immunotherapy for melanoma treatment. Trends Immunol 2010, 31:339-345.
5. Fridman W.H., Galon J., Pages F., Tartour E., Sautes-Fridman C., Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011, 71:5601-5605.
6. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-296.
7. Balsamo M., Scordamaglia F., Pietra G., Manzini C., Cantoni C., Boitano M., et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci USA 2009, 106:20847-20852.
8. Lee J.C., Lee K.M., Kim D.W., Heo D.S. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004, 172:7335-7340.
9. Pietra G., Manzini C., Rivara S., Vitale M., Cantoni C., Petretto A., et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012, 72:1407-1415.
10. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006, 176:1582-1587.
11. Moretta A., Bottino C., Mingari M.C., Biassoni R., Moretta L. What is a natural killer cell. Nat Immunol 2002, 3:6-8.
12. Bottino C., Castriconi R., Pende D., Rivera P., Nanni M., Carnemolla B., et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003, 198:557-567.
13. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223.
14. Moretta L., Biassoni R., Bottino C., Mingari M.C., Moretta A. Human NK-cell receptors. Immunol Today 2000, 21:420-422.
15. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
16. Karre K., Ljunggren H.G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319:675-678.
17. Ciccone E., Pende D., Viale O., Than A., Di Donato C., Orengo A.M., et al. Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2). J Exp Med 1992, 176:963-971.
18. + natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990, 172:1589-1598.
19. + natural killer cells. Role in cell activation and regulation of cytolytic function. J Exp Med 1990, 171:695-714.
20. Moretta A., Vitale M., Bottino C., Orengo A.M., Morelli L., Augugliaro R., et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 1993, 178:597-604.
21. Pende D., Biassoni R., Cantoni C., Verdiani S., Falco M., di Donato C., et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med 1996, 184:505-518.
22. Wagtmann N., Biassoni R., Cantoni C., Verdiani S., Malnati M.S., Vitale M., et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 1995, 2:439-449.
23. Moretta L., Locatelli F., Pende D., Marcenaro E., Mingari M.C., Moretta A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2011, 117:764-771.
24. Freud A.G., Caligiuri M.A. Human natural killer cell development. Immunol Rev 2006, 214:56-72.
25. Freud A.G., Yokohama A., Becknell B., Lee M.T., Mao H.C., Ferketich A.K., et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006, 203:1033-1043.
26. Venstrom J.M., Pittari G., Gooley T.A., Chewning J.H., Spellman S., Haagenson M., et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012, 367:805-816.
27. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 2009, 266:154-181.
28. Moretta L., Ciccone E., Mingari M.C., Biassoni R., Moretta A. Human natural killer cells: origin, clonality, specificity, and receptors. Adv Immunol 1994, 55:341-380.
29. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989, 47:187-376.
30. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
31. + NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci USA 2011, 108:728-732.
32. Fauriat C., Long E.O., Ljunggren H.G., Bryceson Y.T. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010, 115:2167-2176.
33. + B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Immunol Lett 2013, 155:21-23.
34. Locatelli F., Merli P., Rutella S. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies. J Leukoc Biol 2013, 94:1141-1157.
35. Cantoni C., Bottino C., Vitale M., Pessino A., Augugliaro R., Malaspina A., et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999, 189:787-796.
36. Pende D., Parolini S., Pessino A., Sivori S., Augugliaro R., Morelli L., et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999, 190:1505-1516.
37. Pessino A., Sivori S., Bottino C., Malaspina A., Morelli L., Moretta L., et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998, 188:953-960.
38. Sivori S., Vitale M., Morelli L., Sanseverino L., Augugliaro R., Bottino C., et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997, 186:1129-1136.
39. Vitale M., Bottino C., Sivori S., Sanseverino L., Castriconi R., Marcenaro E., et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998, 187:2065-2072.
40. Arnon T.I., Achdout H., Levi O., Markel G., Saleh N., Katz G., et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005, 6:515-523.
41. Brandt C.S., Baratin M., Yi E.C., Kennedy J., Gao Z., Fox B., et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009, 206:1495-1503.
42. Pogge von Strandmann E., Simhadri V.R., von Tresckow B., Sasse S., Reiners K.S., Hansen H.P., et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007, 27:965-974.
43. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
44. Moretta A., Sivori S., Vitale M., Pende D., Morelli L., Augugliaro R., et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995, 182:875-884.
45. Braud V.M., Allan D.S., O'Callaghan C.A., Soderstrom K., D'Andrea A., Ogg G.S., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799.
46. Lopez-Botet M., Perez-Villar J.J., Carretero M., Rodriguez A., Melero I., Bellon T., et al. Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. Immunol Rev 1997, 155:165-174.
47. Aversa F., Terenzi A., Tabilio A., Falzetti F., Carotti A., Ballanti S., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Orthod 2005, 23:3447-3454.
48. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
49. Pende D., Marcenaro S., Falco M., Martini S., Bernardo M.E., Montagna D., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009, 113:3119-3129.
50. Pfeiffer M.M., Feuchtinger T., Teltschik H.M., Schumm M., Muller I., Handgretinger R., et al. Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children. Haematologica 2010, 95:1381-1388.
51. Stern M., Ruggeri L., Mancusi A., Bernardo M.E., de Angelis C., Bucher C., et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008, 112:2990-2995.
52. Aversa F., Tabilio A., Velardi A., Cunningham I., Terenzi A., Falzetti F., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998, 339:1186-1193.
53. Ciceri F., Labopin M., Aversa F., Rowe J.M., Bunjes D., Lewalle P., et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008, 112:3574-3581.
54. Klingebiel T., Cornish J., Labopin M., Locatelli F., Darbyshire P., Handgretinger R., et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010, 115:3437-3446.
55. Bachar-Lustig E., Rachamim N., Li H.W., Lan F., Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995, 1:1268-1273.
56. Reisner Y., Hagin D., Martelli M.F. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011, 118:6006-6017.
57. Blom B., Spits H. Development of human lymphoid cells. Annu Rev Immunol 2006, 24:287-320.
58. Spits H., Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 2012, 30:647-675.
59. Grzywacz B., Kataria N., Blazar B.R., Miller J.S., Verneris M.R. Natural killer-cell differentiation by myeloid progenitors. Blood 2011, 117:3548-3558.
60. Perez S.A., Sotiropoulou P.A., Gkika D.G., Mahaira L.G., Niarchos D.K., Gritzapis A.D., et al. A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood 2003, 101:3444-3450.
61. + cord blood precursors toward NK cells. Int Immunol 2008, 20:565-575.
62. Aliahmad P., de la Torre B., Kaye J. Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat Immunol 2010, 11:945-952.
63. Yun S., Lee S.H., Yoon S.R., Kim M.S., Piao Z.H., Myung P.K., et al. TOX regulates the differentiation of human natural killer cells from hematopoietic stem cells in vitro. Immunol Lett 2011, 136:29-36.
64. Della Chiesa M., Falco M., Podesta M., Locatelli F., Moretta L., Frassoni F., et al. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. Blood 2012, 119:399-410.
65. Chan A., Hong D.L., Atzberger A., Kollnberger S., Filer A.D., Buckley C.D., et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 2007, 179:89-94.
66. Juelke K., Killig M., Luetke-Eversloh M., Parente E., Gruen J., Morandi B., et al. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 2010, 116:1299-1307.
67. Chaleff S., Otto M., Barfield R.C., Leimig T., Iyengar R., Martin J., et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy 2007, 9:746-754.
68. Bari R., Rujkijyanont P., Sullivan E., Kang G., Turner V., Gan K., et al. Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation. J Clin Orthod 2013, 31:3782-3790.
69. Cooley S., Trachtenberg E., Bergemann T.L., Saeteurn K., Klein J., Le C.T., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 113:726-732.
70. Stringaris K., Adams S., Uribe M., Eniafe R., Wu C.O., Savani B.N., et al. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant 2010, 16:1257-1264.
71. Cooley S., Weisdorf D.J., Guethlein L.A., Klein J.P., Wang T., Le C.T., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
72. Hsu K.C., Liu X.R., Selvakumar A., Mickelson E., O'Reilly R.J., Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 2002, 169:5118-5129.
73. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005, 5:201-214.
74. Fauriat C., Ivarsson M.A., Ljunggren H.G., Malmberg K.J., Michaelsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2010, 115:1166-1174.
75. Curti A., Ruggeri L., D'Addio A., Bontadini A., Dan E., Motta M.R., et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011, 118:3273-3279.
76. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
77. Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Orthod 2010, 28:955-959.
78. Stern M., Passweg J.R., Meyer-Monard S., Esser R., Tonn T., Soerensen J., et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant 2013, 48:433-438.
79. + progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant 2010, 45:1038-1046.
80. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
81. Lang P., Pfeiffer M., Teltschik H.M., Schlegel P., Feuchtinger T., Ebinger M., et al. Natural killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors. Best Pract Res Clin Haematol 2011, 24:403-411.
82. Pfeiffer M., Schumm M., Feuchtinger T., Dietz K., Handgretinger R., Lang P. Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia. Br J Haematol 2007, 138:97-100.
83. Leong J.W., Chase J.M., Romee R., Schneider S.E., Sullivan R.P., Cooper M.A., et al. Pre-activation with IL-12, IL-15, and IL-18 induces CD25 and a functional high affinity IL-2 receptor on human cytokine-induced memory-like NK cells. Biol Blood Marrow Transplant 2014.
84. Ni J., Miller M., Stojanovic A., Garbi N., Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 2012, 209:2351-2365.
85. Romee R., Schneider S.E., Leong J.W., Chase J.M., Keppel C.R., Sullivan R.P., et al. Cytokine activation induces human memory-like NK cells. Blood 2012, 120:4751-4760.
86. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:557-561.
87. Golay J., Introna M. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys 2012, 526:146-153.
88. Wu J., Edberg J.C., Redecha P.B., Bansal V., Guyre P.M., Coleman K., et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997, 100:1059-1070.
89. Deguine J., Breart B., Lemaitre F., Bousso P. Cutting edge: tumor-targeting antibodies enhance NKG2D-mediated NK cell cytotoxicity by stabilizing NK cell-tumor cell interactions. J Immunol 2012, 189:5493-5497.
90. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
91. Kellner C., Bruenke J., Horner H., Schubert J., Schwenkert M., Mentz K., et al. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Lett 2011, 303:128-139.
92. Gleason M.K., Verneris M.R., Todhunter D.A., Zhang B., McCullar V., Zhou S.X., et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther 2012, 11:2674-2684.
93. Jiang H., Zhang W., Shang P., Zhang H., Fu W., Ye F., et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol 2013.
94. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
95. Dutour A., Marin V., Pizzitola I., Valsesia-Wittmann S., Lee D., Yvon E., et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv Hematol 2012, 2012:683065.
96. Casucci M., Nicolis di Robilant B., Falcone L., Camisa B., Norelli M., Genovese P., et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 2013, 122:3461-3472.
97. Tettamanti S., Marin V., Pizzitola I., Magnani C.F., Giordano Attianese G.M., Cribioli E., et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol 2013, 161:389-401.
98. Ochi T., Fujiwara H., Okamoto S., An J., Nagai K., Shirakata T., et al. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood 2011, 118:1495-1503.